BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20514021)

  • 1. TLR9 triggering in Burkitt's lymphoma cell lines suppresses the EBV BZLF1 transcription via histone modification.
    Zauner L; Melroe GT; Sigrist JA; Rechsteiner MP; Dorner M; Arnold M; Berger C; Bernasconi M; Schaefer BW; Speck RF; Nadal D
    Oncogene; 2010 Aug; 29(32):4588-98. PubMed ID: 20514021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IRAK4 is essential for TLR9-induced suppression of Epstein-Barr virus BZLF1 transcription in Akata Burkitt's lymphoma cells.
    Jordi M; Marty J; Mordasini V; Lünemann A; McComb S; Bernasconi M; Nadal D
    PLoS One; 2017; 12(10):e0186614. PubMed ID: 29088270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TLR9 agonists induced cell death in Burkitt's lymphoma cells is variable and influenced by TLR9 polymorphism.
    Noack J; Jordi M; Zauner L; Alessi D; Burch A; Tinguely M; Hersberger M; Bernasconi M; Nadal D
    Cell Death Dis; 2012 Jun; 3(6):e323. PubMed ID: 22717578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of Epstein-Barr virus on host gene expression in Burkitt's lymphoma cell lines].
    Broderick P; Hubank M; Sinclair A
    Ai Zheng; 2009 Aug; 28(8):813-21. PubMed ID: 19664326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Mechanism-Based Targeted Screen To Identify Epstein-Barr Virus-Directed Antiviral Agents.
    Li X; Akinyemi IA; You JK; Rezaei MA; Li C; McIntosh MT; Del Poeta M; Bhaduri-McIntosh S
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32796077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IRF4 promotes Epstein-Barr virus activation in Burkitt's lymphoma cells.
    Gao Y; Wang L; Lei Z; Li J; Forrest JC; Liang X
    J Gen Virol; 2019 May; 100(5):851-862. PubMed ID: 30907723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. hTERT inhibition triggers Epstein-Barr virus lytic cycle and apoptosis in immortalized and transformed B cells: a basis for new therapies.
    Giunco S; Dolcetti R; Keppel S; Celeghin A; Indraccolo S; Dal Col J; Mastorci K; De Rossi A
    Clin Cancer Res; 2013 Apr; 19(8):2036-47. PubMed ID: 23444223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia-inducible factor-1α plays roles in Epstein-Barr virus's natural life cycle and tumorigenesis by inducing lytic infection through direct binding to the immediate-early BZLF1 gene promoter.
    Kraus RJ; Yu X; Cordes BA; Sathiamoorthi S; Iempridee T; Nawandar DM; Ma S; Romero-Masters JC; McChesney KG; Lin Z; Makielski KR; Lee DL; Lambert PF; Johannsen EC; Kenney SC; Mertz JE
    PLoS Pathog; 2017 Jun; 13(6):e1006404. PubMed ID: 28617871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A molecular link between malaria and Epstein-Barr virus reactivation.
    Chêne A; Donati D; Guerreiro-Cacais AO; Levitsky V; Chen Q; Falk KI; Orem J; Kironde F; Wahlgren M; Bejarano MT
    PLoS Pathog; 2007 Jun; 3(6):e80. PubMed ID: 17559303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactivation of Epstein-Barr Virus by HIF-1α Requires p53.
    Kraus RJ; Cordes BA; Sathiamoorthi S; Patel P; Yuan X; Iempridee T; Yu X; Lee DL; Lambert PF; Mertz JE
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32641480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 5' regulatory sequences of active miR-146a promoters are hypomethylated and associated with euchromatic histone modification marks in B lymphoid cells.
    Szenthe K; Koroknai A; Banati F; Bathori Z; Lozsa R; Burgyan J; Wolf H; Salamon D; Nagy K; Niller HH; Minarovits J
    Biochem Biophys Res Commun; 2013 Apr; 433(4):489-95. PubMed ID: 23528241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma.
    Niedobitek G; Agathanggelou A; Rowe M; Jones EL; Jones DB; Turyaguma P; Oryema J; Wright DH; Young LS
    Blood; 1995 Jul; 86(2):659-65. PubMed ID: 7605996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of Epstein-Barr virus (EBV) reactivation in Raji cells by doxorubicin and cisplatin.
    Hsu CH; Hergenhahn M; Chuang SE; Yeh PY; Wu TC; Gao M; Cheng AL
    Anticancer Res; 2002; 22(6C):4065-71. PubMed ID: 12553034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune activation suppresses initiation of lytic Epstein-Barr virus infection.
    Ladell K; Dorner M; Zauner L; Berger C; Zucol F; Bernasconi M; Niggli FK; Speck RF; Nadal D
    Cell Microbiol; 2007 Aug; 9(8):2055-69. PubMed ID: 17419714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphatidylinositol 3-kinase is a determinant of responsiveness to B cell antigen receptor-mediated Epstein-Barr virus activation.
    Iwakiri D; Takada K
    J Immunol; 2004 Feb; 172(3):1561-6. PubMed ID: 14734735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1.
    Robinson AR; Kwek SS; Kenney SC
    PLoS Pathog; 2012 Feb; 8(2):e1002516. PubMed ID: 22346751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional role of phosphatidylinositol 3-kinase/Akt pathway on cell growth and lytic cycle of Epstein-Barr virus in the Burkitt's lymphoma cell line, P3HR-1.
    Mori T; Sairenji T
    Virus Genes; 2006 Jun; 32(3):327-34. PubMed ID: 16732486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone Loaders CAF1 and HIRA Restrict Epstein-Barr Virus B-Cell Lytic Reactivation.
    Zhang Y; Jiang C; Trudeau SJ; Narita Y; Zhao B; Teng M; Guo R; Gewurz BE
    mBio; 2020 Oct; 11(5):. PubMed ID: 33109754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BZLF1 governs CpG-methylated chromatin of Epstein-Barr Virus reversing epigenetic repression.
    Woellmer A; Arteaga-Salas JM; Hammerschmidt W
    PLoS Pathog; 2012 Sep; 8(9):e1002902. PubMed ID: 22969425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular differentiation regulator BLIMP1 induces Epstein-Barr virus lytic reactivation in epithelial and B cells by activating transcription from both the R and Z promoters.
    Reusch JA; Nawandar DM; Wright KL; Kenney SC; Mertz JE
    J Virol; 2015 Feb; 89(3):1731-43. PubMed ID: 25410866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.